Third Harmonic Bio Inc (THRD) Forecast, Price Target & Analyst Ratings
NASDAQ:THRD • US88427A1079
5.38 USD
0 (-0.09%)
At close: Jul 30, 2025
5.38 USD
0 (0%)
After Hours: 7/30/2025, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Third Harmonic Bio Inc (THRD).
Forecast Snapshot
Consensus Price Target
$3.06
-43.12% Downside
Next Earnings Forecast
Release DateNov 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.23
Revenue Estimate
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.06
Upside
-43.12%
From current price of $5.38 to mean target of $3.06, Based on 6 analyst forecasts
Low
$3.03
Median
$3.06
High
$3.15
Price Target Revisions
1 Month
-29.41%
3 Months
-34.45%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for THRD. The average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.
The average price target has been revised downward by 34.45% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
THRD was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about THRD.
In the previous month the buy percentage consensus was at a similar level.
THRD was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-28 | Stifel | Downgrade | Buy -> Hold |
| 2025-02-12 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-02-11 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2024-08-09 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2024-06-18 | Stifel | Initiate | Buy |
| 2024-06-07 | Raymond James | Initiate | Outperform |
| 2023-08-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2022-12-16 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-12-16 | Jefferies | Downgrade | Buy -> Hold |
| 2022-10-10 | Cowen & Co. | Initiate | Outperform |
| 2022-10-10 | Morgan Stanley | Initiate | Overweight |
| 2022-10-10 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateNov 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.23
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q9.77%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
7.07%
Next Earnings Summary
THRD is expected to report earnings on 11/5/2025. The consensus EPS estimate for the next earnings is -0.23 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A 62.50% | ||||||
| EBITDA YoY % growth | N/A | N/A | -37.71M | -43.919M -16.47% | -58.823M -33.94% | N/A 12.61% | N/A -11.80% | N/A -44.66% | N/A 31.31% | N/A -6.66% | N/A -6.98% | N/A 39.85% | N/A 489.43% | |
| EBIT YoY % growth | -11.12M | -19M -70.86% | -37.71M -98.47% | -43.954M -16.56% | -58.872M -33.94% | N/A 10.77% | N/A 16.50% | N/A | N/A -2.33% | N/A | N/A 2.27% | N/A 18.60% | N/A 17.14% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -0.95 61.09% | -1.27 -33.68% | N/A 26.11% | N/A -3.26% | N/A | N/A | N/A -17.89% | N/A -17.86% | N/A 78.79% | N/A 792.86% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.23 9.77% | -0.18 44.36% | -0.16 66.00% |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | -14.28M -1.67% | -14.28M 16.18% | -14.28M 12.87% |
| EBIT Q2Q % growth | -13.77M 2.13% | -11.73M 31.30% | -10.71M 34.85% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
7.35%
EPS Next 5 Year
1.93%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-16.07%
EBIT Next 5 Year
-2.76%
Third Harmonic Bio Inc / THRD Forecast FAQ
What is the price target for THRD stock?
6 analysts have analysed THRD and the average price target is 3.06 USD. This implies a price decrease of -43.12% is expected in the next year compared to the current price of 5.38.
What is the next earnings date for THRD stock?
Third Harmonic Bio Inc (THRD) will report earnings on 2025-11-05.
Can you provide the consensus estimates for Third Harmonic Bio Inc next earnings?
The consensus EPS estimate for the next earnings of Third Harmonic Bio Inc (THRD) is -0.23 USD and the consensus revenue estimate is 0 USD.